This episode of the BioCentury Show podcast features Forbion Managing Partner Sander Slootweg.
In conversation with Stephen Hansen, Sander shares his perspectives on the current state of European biotech financing. He also discusses developments in the biotech sectors in China and Korea, explores the role of green investing, and explains why he continues to see a need for a European equivalent of NASDAQ, though not as an exit pathway for Forbion-backed companies.
